Andere Sprachen Shionogi & Co., Ltd.

Aktien

855648

JP3347200002

4507

Verzögert Japan Exchange Andere Börsenplätze 08:00:00 30.05.2024			% 5 Tage	% 1. Jan.
6’976 ^JPY	-0.20%		+2.98%	+2.62%

14.05.	Japan's Nikkei driftet seitwärts, da weitere Gewinne und US CPI erwartet werden	RE
13.05.	MÄRKTE ASIEN/Börsen wenig verändert - Mazda sehr schwach	DJ

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Shionogi & Co., Ltd. - Launch of the Gram-negative Bacterial Infection Treatment FETROJA 1g, in Taiwan	29.05.
Japan's Nikkei drifts sideways as more earnings, US CPI awaited	14.05.
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease	13.05.
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial	13.05.
Shionogi - Notice of Collaboration Agreement for the Discovery and Development of Novel Malaria Preventive Drugs with Nagasaki University, National Institute of Infectious Diseases, and MMV, Supported by the GHIT Fund	09.05.
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	30.04.
Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	25.04.
Shionogi & Co., Ltd. - Notice regarding introduction of a Restricted Stock Compensation Plan for Vice Presidents	23.04.
Shionogi & Co., Ltd. - Notice Regarding Completion of Cancellation of Treasury Shares	19.04.
ESCMID Global 2024, Shionogi presents real-world data demonstrating efficacy of Fetcroja, Fetroja in critically ill patients with certain difficult-to-treat bacterial infections	19.04.
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares	19.04.
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol)	18.04.
Shionogi - The European Commission Grants Orphan Medicinal Product Designation for Zatolmilast, a Potential First-In-Class Treatment Being Investigated for Fragile X Syndrome	12.04.
Shionogi Completes Up to 75 Billion Yen Share Buyback	29.03.
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.	28.03.
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million.	22.03.
FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd.	21.03.
Shionogi & Co., Ltd. - Recognized as One of the Highest-Ranking Companies on the Supplier Engagement Rating by CDP for the Fourth Consecutive Year	08.03.
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial	07.03.
Shionogi & Co., Ltd. - Notice Regarding the Status of Acquisition of Own Shares	06.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Shionogi & Co., Ltd.

Aktien

855648

JP3347200002

4507

Andere Sprachen

Filter